Understanding how cancer immunotherapy can lead to diabetes
Official title: Elucidating mechanisms of checkpoint inhibitor-induced diabetes
Funded at Yale University · NIH-10930958 · Data updated 2026-11-12
This study is looking into how cancer treatments, especially those that boost the immune system, can sometimes lead to diabetes, and it's aimed at helping patients who might experience this side effect by finding ways to prevent it.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 18, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $173,515 |
| NIH project number | 5K08CA282972-02 |
| Project ID | NIH-10930958 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving checkpoint inhibitor therapies and may be at risk for developing diabetes.
✕Less likely to help
Patients who are not undergoing cancer treatment or those who do not have a risk of developing diabetes from immunotherapy may not benefit from this research.
What this research studies
This research investigates the mechanisms behind diabetes that can occur as a side effect of cancer immunotherapy, specifically checkpoint inhibitors. The principal investigator, Dr. Ana Perdigoto, aims to identify how immune cells interact with pancreatic cells to cause this condition. By studying these immune-related adverse events, the research seeks to uncover potential therapeutic targets to mitigate these complications for patients undergoing cancer treatment. The work is conducted at Yale University, leveraging a collaborative environment and expert mentorship.
Why it matters
Potential benefit: If successful, this research could lead to better management strategies for diabetes induced by cancer immunotherapy, improving patient quality of life.
How similar studies have gone: Previous research has shown that understanding immune-related adverse events can lead to significant advancements in managing complications from cancer therapies, indicating a promising avenue for this investigation.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Perdigoto, Ana Luisa Jordao — Yale University
- Study coordinator: Perdigoto, Ana Luisa Jordao
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.